Tous les communiqués de presse

- Valbiotis announces the last visit of the last patient in the Phase II/III REVERSE-IT study on TOTUM•63, in partnership with Nestlé Health Science.

Voir le communiqué de presse

- 2022 turnover: €226.6 million (IN FRENCH).

Voir le communiqué de presse

- Approval of the agreement concluded by METabolic EXplorer with its main partners on 23 December 2022 under the conciliation procedure (IN FRENCH).

Voir le communiqué de presse

- Inauguration of the new production unit of CARBOGEN AMCIS SAS at Biopôle Clermont-Limagne (Saint-Beauzire, Puy de Dôme) Friday, February 3, 2023 (IN FRENCH).

Voir le communiqué de presse

- Valbiotis announces positive results in the bioavailability and mode of action TOTUM•854 clinical study, against high blood pressure.

Voir le communiqué de presse

- Provisional suspension of the liquidity contract (IN FRENCH).

Voir le communiqué de presse

- 2023 Financial Schedule (IN FRENCH).

Voir le communiqué de presse

- Provision of preparatory documents for the Extraordinary General Assembly (IN FRENCH).

Voir le communiqué de presse

- Valbiotis announces its roadmap for 2023: a pivotal year in the execution of its clinical, industrial and commercial strategy.

Voir le communiqué de presse

- METabolic EXplorer secures financing for deployment of its strategy.

Voir le communiqué de presse